Cytek Biosciences, Inc. (CTKB) reported a quarterly loss of $0.01 per share for the period ending December 2025, falling short of the Zacks Consensus Estimate of a profit of $0.02 per share. This marks a significant decline from earnings of $0.07 per share in the same quarter last year. The company’s revenue for the quarter was $62.14 million, slightly exceeding estimates by 0.23% and up from $57.48 million a year prior.
Cytek has only surpassed consensus EPS estimates once in the last four quarters, delivering an earnings surprise of -166.67% this time. The stock has declined approximately 13.5% year-to-date, contrasting with the S&P 500’s gain of 1.5%. Current consensus estimates for the upcoming quarter are a loss of $0.04 per share on sales of $44.44 million, with annual projections at a loss of $0.02 per share and revenues of $207.38 million.
